| Φ   | Uchealth  Southern Colorado Region  OUTPATIENT (Age ≥18) Antibiogram  January 2022 – December 2022 | Amoxicillin/Clavulanic Acid<br>(Augmentin) | Ampicillin +/- Sulbactam<br>(Unasyn) ◊ | Cefazolin * | Cefepime | Ceftriaxone<br>(Non-Meningitis/Meningitis) | Ciprofloxacin* | Clindamycin | Erythromycin<br>(Use Azithromycin) | Gentamicin ‡ | Levofloxacin | Meropenem | Oxacillin | Penicillin (Non-meningitis<br>/Meningitis/Oral) | Piperacillin/Tazobactam<br>(Zosyn) | Tetracycline<br>(Use Doxycycline) | Tobramycin | Trimethoprim/Sulfamethoxazole (Bactrim) | Vancomycin |                                  |           |
|-----|--|--|--|-------------|----------|--|----------------|-------------|------------------------------------|--------------|--------------|-----------|-----------|---|------------------------------------|-----------------------------------|------------|---|------------|----------------------------------|-----------|
| P.  | Enterobacter spp. (37)   | R  | R                                      | R           | 100      | 91   | 94             |             |                                    | 100          | 89           | 100       |           |   | 94                                 | 91                                | 100        | 97                                      |            | Enterobacter spp. (37)           |           |
| -lo | Enterococcus faecalis (67)   |  | 100                                    | R           | R        | R  |                |             |                                    |              |              |           | R         |   |                                    |                                   |            | R                                       | 100        | Enterococcus faecalis (67)       |           |
| _   | Escherichia spp. (131)   | 88   | 58                                     | 86          | 93       | 92   | 90             |             |                                    | 91           | 77           | 100       |           |   | 100                                | 76                                | 91         | 80                                      |            | Escherichia spp.<br>(131)        |           |
|     | Pseudomonas<br>aeruginosa (55)   | R  | R                                      | R           | 90       | R  | 87             |             |                                    |              | 85           | 94        |           |   | 90                                 | R                                 | 96         | R                                       |            | Pseudomonas<br>aeruginosa (55)   | ine       |
|     | MSSA (288)   |  |  | 100         |          |  |                | 76          | 67                                 | 99           |              |           | 100       | R   |                                    | 92                                |            | 98                                      | 100        | MSSA (288)                       | Non-Urine |
|     | MRSA (121)   | R  | R                                      | R           | R        | R  |                | 79          | 18                                 | 98           |              | R         | R         | R   | R                                  | 94                                |            | 95                                      | 100        | MRSA (121)                       | No        |
|     | Staphylococcus epidermidis (74)  |  |  | 36          |          |  |                | 64          | 36                                 | 93           |              |           | 36        | R   |                                    | 75                                |            | 64                                      | 100        | Staphylococcus epidermidis (74)  |           |
|     | All Enterobacterales (272)   | 70   | 49                                     | 85          | 96       | 94   | 90             |             |                                    | 95           | 80           | 100       |           |   | 98                                 | 74                                | 93         | 84                                      |            | All<br>Enterobacterales<br>(272) |           |

Organism (# of isolates)

% susceptible

R = Intrinsically resistant.

spp = species

## Notes:

• Includes outpatients at MHN, MHC, Grandview, and PPRH emergency departments who were discharged from the emergency department as well as urgent care and freestanding emergency departments that are part of UCHealth. Inpatient rehab is also included in this data.

## Non-Susceptible Isolate Frequencies % (N) All adults, All Sources, All Regional Locations N/N → Erta/Mero [often mero same isolate as erta]

CRE = 1.31% (45) 20/2 *E. cloacae*  MRSA = 31.7% (290) VRE = 6.3% (65)

6/0 E. coli

CRPA = 8.6% (24)CRAsp = 0%

5/2 S. marcescens

5/0 E. aerogenes

3/2 K. pneumoniae

3/0 P. mirabilis

2/0 C. freundii

1/0 P. rettgeri

<sup>\* =</sup> Due to breakpoint limitation % susceptible & intermediate shown; for ciprofloxacin only applies to Enterobacterales group

t = For synergy for gram-positive infections, not appropriate as monotherapy for gram-positives.

<sup>♦ =</sup> Ampicillin/sulbactam susceptibility is approximately the same or only a few percentage points better than ampicillin by itself except for *K. pneumo* which it should still maintain decent activity against

|       | Southern Colorado Region OUTPATIENT (Age ≥18) Antibiogram  January 2022 – December 2022 | Amoxicillin/Clavulanic Acid<br>(Augmentin) | Ampicillin +/- Sulbactam<br>(Unasyn) ◊ | Cefazolin | Cefepime | Ceftriaxone<br>(Non-Meningitis/Meningitis) | Ciprofloxacin* | Gentamicin ŧ | Levofloxacin | Meropenem | Nitrofurantoin | Oxacillin | Penicillin (Non-meningitis<br>/Meningitis/Oral) | Piperacillin/Tazobactam<br>(Zosyn) | Tetracycline<br>(Use Doxycycline) | Tobramycin | Trimethoprim/Sulfamethoxazole (Bactrim) | Vancomycin |                                   |       |
|-------|---|--|--|-----------|----------|--|----------------|--------------|--------------|-----------|----------------|-----------|---|------------------------------------|-----------------------------------|------------|---|------------|-----------------------------------|-------|
| -     | Enterobacter spp. (208)   | R  | R                                      | R         | 95       | 80   | 97             | 99           | 94           | 99        | 27             |           |   | 83                                 |                                   | 98         | 97                                      |            | Enterobacter spp. (208)           |       |
| Urine | Enterococcus faecalis (396)   |  | 100                                    | R         | R        | R  | 92             |              | 92           |           | 99             | R         |   |                                    |                                   |            | R                                       | 100        | Enterococcus faecalis (396)       |       |
|       | Escherichia spp.<br>(3998)  | 88   | 63                                     | 92        | 96       | 94   | 87             | 93           | 79           | 100       | 97             |           |   | 97                                 |                                   | 93         | 81                                      |            | Escherichia spp. (3998)           |       |
|       | Klebsiella<br>oxytoca (126)   | 95   | R                                      |           | 96       | 92   | 98             | 98           | 96           | 100       | 92             |           |   | 94                                 |                                   | 97         | 92                                      |            | Klebsiella oxytoca (126)          |       |
|       | Klebsiella<br>pneumoniae (661)  | 97   | R                                      | 96        | 98       | 96   | 95             | 98           | 91           | 99        | 39             |           |   | 97                                 |                                   | 98         | 94                                      |            | Klebsiella<br>pneumoniae (661)    | Urine |
|       | Proteus<br>mirabilis (202)  | 99   | 89                                     | 97        | 97       | 97   | 89             | 92           | 88           | 100       | R              |           |   | 100                                | R                                 | 93         | 88                                      |            | Proteus<br>mirabilis (202)        | 'n    |
|       | Pseudomonas<br>aeruginosa (195)   | R  | R                                      | R         | 95       | R  | 78             |              | 77           | 91        | R              |           |   | 91                                 | R                                 | 99         | R                                       |            | Pseudomonas<br>aeruginosa (195)   |       |
|       | Staphylococcus epidermidis (209)  |  |  | 55        |          |  |                | 96           |              |           | 99             | 55        | R   |                                    | 83                                |            | 68                                      | 100        | Staphylococcus epidermidis (209)  |       |
|       | All<br>Enterobacterales<br>(5158)   | 84   | 57                                     | 94        | 96       | 94   | 89             | 94           | 82           | 99        | 84             |           |   | 97                                 |                                   | 94         | 84                                      |            | All<br>Enterobacterales<br>(5158) |       |

Organism (# of isolates)

R = Intrinsically resistant.

% susceptible spp = species

- \* = Due to breakpoint limitation % susceptible & intermediate shown; for ciprofloxacin only applies to Enterobacterales group
- # = For synergy for gram-positive infections, not appropriate as monotherapy for gram-positives.
- ◊ = Ampicillin/sulbactam susceptibility is approximately the same or only a few percentage points better than ampicillin by itself except for K. pneumo which it should still maintain decent activity against

#### Notes:

- Routine testing of urine isolate of *Staph saprophyticus* is not advised because infections respond to concentrations achieved in urine of antimicrobial agents commonly used to treat acute, uncomplicated UTIs (e.g. cephalexin, nitrofurantoin, trimethoprim/sulfamethoxazole, or fluoroquinolones). It is intrinsically resistant to fosfomycin.
- Includes outpatients at MHN, MHC, Grandview, and PPRH emergency departments who were discharged from the emergency department as well as urgent care and freestanding emergency departments that are part of UCHealth. Inpatient rehab is also included in this data.

Non-Susceptible Isolate Frequencies % (N)
All <u>adults</u>, All Sources, All Regional Locations
N/N → Erta/Mero [often mero same isolate as erta]

CRE = 1.31% (45)

20/2 E. cloacae 6/0 E. coli

5/2 S. marcescens

5/0 E. aerogenes

3/2 K. pneumoniae

3/0 P. mirabilis 2/0 C. freundii

1/0 P. rettgeri

MRSA = 31.7% (290) VRE = 6.3% (65) CRPA = 8.6% (24)

CRAsp = 0%

MDRO PROTOCOL: An automatic infectious disease consult will occur at MHN, MHC, and GVH for CRE/CRPA/CRAB/CRO/C. auris from ANY site and blood specimens positive for S. aureus, S. lugdunensis, Enterococcus, or Yeast in inpatient adult patients age 15 and over. Unless there are extenuating circumstances, the patient will be seen within 24 hours.

## **Urine Culture Reflex Guidance (Outpatient):**

- A urine sample will be cultured when the patient is
   13 years old OR when reflex criteria are met:
  - Positive leukocyte esterase AND/OR
  - Positive nitrite <u>and</u> leukocytes > 10/hpf
  - No reflex culture will be done when epithelial cells > 10/hpf (indicative of contaminated specimen, unsatisfactory for culture)
- Asymptomatic bacteriuria does not require therapy. If the patient does not have UTI symptoms, urine culture is not indicated unless the patient is pregnant, pediatric, undergoing invasive urinary tract procedures, or immunocompromised.
- If culture is indicated; re-submit a clean catch or catheterized urine if it has been >24 hours from initial collection of UA, otherwise add-on from UA.
- The negative chemical and/or microscopic urinalysis has a very high specificity and a very high negative predictive value for absence of a UTI.

## United States Anaerobic Susceptibility Data 2013-2016 % Susceptible

|                         | Amp/Sulb | Pip/Tazo | Cefoxitin | Meropenem | Clindamycin | Metronidazole |
|-------------------------|----------|----------|-----------|-----------|-------------|---------------|
| Anaerobic<br>GPC*       | -        | 99       | -         | 100       | 97          | 100           |
| Bacteroides fragilis    | 84       | 96       | 100       | 93        | 26          | 100           |
| B. fragilis group       | 74       | 94       | 70        | 95        | 33          | 100           |
| Clostridium perfringens | 100      | 100      |           | 100       | 83          | 100           |
| Fusobacterium spp       | 100      | 96       | -         | 100       | 77          | 95            |

\*Anaerobic gram-positive cocci = Peptococcus, Peptostreptococcus, Fingoldia, Peptoniphilus, and Anaerococcus species

- = no data available GPC = Gram Positive Cocci

### Inducible Resistance; All ages/sources/locations:

MRSA inducible clindamycin resistance 3% MSSA inducible clindamycin resistance 19%

Grp B Strep Clinda = 47% Sensitive; 28% of the total resistance was due to "inducible mechanism" during this time period from 39 resistant isolates tested.

While susceptibility testing may indicate that bacteria are susceptible to an antibiotic, some bacteria may have enzymes that can be "turned on" or induced (thus inducible resistance) in vitro resulting in antibiotic resistance.

## **Blood Cultures (Outpatient)** Frequency of Pathogen Isolation:

1. *E. coli* (46) 5. MRSA (8)

2. MSSA (16) 6/7. S. pneumoniae, Viridans 3. S. epidermidis (13) streptococci (7 each)

4. K. pneumoniae (9) 8. E. faecalis (6)

| Types of Isolation and Associated Organisms |  |  |   |  |  |  |  |  |
|---|--|--|---|--|--|--|--|--|
| Isolation                                   | Required<br>PPE                                      | Organisms/<br>Diseases<br>(active or r/o)                        | Comments  |  |  |  |  |  |
| Contact                                     | Gowns & gloves                                       | MRSA, VRE, MDROs and draining abscesses                          | MRSA can be cleared with nares/axilla/groin cultures.   |  |  |  |  |  |
| Special<br>Contact                          | Gowns &<br>gloves,<br>soap &<br>water for            | C. diff  Diapered or incontinent                                 | Isolate until discontinued by physician or Infection Preventionist.   |  |  |  |  |  |
| Contact                                     | hand<br>hygiene                                      | pts with: Shigella, Shigella, & Norovirus                        | Isolate for duration of illness.  |  |  |  |  |  |
| Droplet                                     | Mask, eye<br>protection<br>rec'd;                    | Influenza  | Isolate for 7 days from<br>onset of sx or 24 hrs after<br>resolution of fever & resp<br>sx whichever is longer.   |  |  |  |  |  |
| Бторієї                                     | gowns &<br>gloves as<br>necessary                    | Neisseria meningitides,<br>meningitis                            | Isolation until pt on abxs for 24 hrs. Viral or aspectic meningitis → Standard precautions.   |  |  |  |  |  |
|   |  | Tuberculosis   | 3 negative AFB AND 2 negative PCR required to rule out.   |  |  |  |  |  |
|   | PAPR or<br>N95,<br>gowns &                           | Varicella (Chickenpox)   | Airborne/contact until lesions dry and crusted over.  |  |  |  |  |  |
| Airborne                                    | gloves as<br>needed<br>per<br>standard<br>precaution | Varicella Zoster<br>(Shingles)                                   | Airborne/contact for immunocomp'd pts or disseminated shingles infection. For non-immunocomp'd pts and/or shingles confined to one area on body → Standard precautions. |  |  |  |  |  |
| Droplet/<br>Contact<br>Peds Units           | Gowns,<br>gloves, &<br>mask                          | RSV, Enterovirus,<br>Acute respiratory<br>illness, Bronchiolitis | Isolate for duration of illness.  |  |  |  |  |  |
|   |  | ns? Possible Employee E ection Prevention at 719-                |   |  |  |  |  |  |

For more information search, "isolation guidelines" on The Source



# Southern Colorado Region OUTPATIENT Adult (Age ≥18) Antibiogram

January 2022 - December 2022

MICROBIOLOGY 719-365-5686

Nathan D. Johnston, DO – Medical Director

Elizabeth Kleiner, MD – Infectious Disease Physician

Alex Novin, PharmD, BCPS, BCIDP Infectious Disease Clinical Pharmacist

Amery Vilander, MT (ASCP) – Microbiology Manager

Krenza Ortiz, MLS (ASCP)<sup>CM</sup> – Microbiology Medical Laboratory Scientist, Molecular Lead